01 October 2012 | Analysis | By BioSpectrum Bureau
ABLE-DBT report estimates Indian biotech to reach $100 billion from its current $4 billion by 2025
ABLE-DBT report: Indian Biotechnology - The Roadmap to the Next Decade and Beyond
Addressing Accessibility an...
Can Test, Treat, Track Beat...
“AI will be integrally invo...
How Indian Biotech Investme...
“We anticipate India will adopt dec
“Because of its specificity and sel
Samsung Biologics signs MoU with Se
Kimer Med inks contract worth NZD $
Queensland's Southern RNA joins for
US FDA clears Beckman Coulter Life
Is the APAC region addressing accessibility and affordability of cell & gene therapies?